Expertise in the use of Accelerator Mass Spectrometry will be added to Roadmap to Clinical Trials
Molecular Profiles and Maryland, US-based Xceleron have entered into a partnership to assist drug developers in improving their efficiency during clinical development.
This collaboration extends Molecular Profiles’ new Roadmap to Clinical Trials enabling technologies platform, launched earlier this month.
The company also has complementary collaborations in place with Onyx Scientific and XenoGesis that broaden its expertise to give clients an end-to-end solution using a connected network of industry experts allowing it to compete with larger CROs.
Xceleron’s expertise in the use of Accelerator Mass Spectrometry (AMS) analytical technology in pharmaceutical product applications will be added to Roadmap, which was created to support companies with the rapid development of standard and complex drug products.
Along with improving the quality and accuracy of clinical data based on drug disposition, the transatlantic alliance aims to support early proof of concept studies and to assist drug innovators with more assured translation.
Claire Madden-Smith, Commercial Director at Molecular Profiles, said: 'We are very pleased to have this alliance with Xceleron given the company’s well-respected and long-standing reputation in the AMS technology field on an international level.
'The Xceleron offering is a natural addition to our Roadmap to Clinical Trials platform, which is about assisting clients in choosing a development pathway that will be the most time-, cost- and volume-efficient route forward.'
Established in 1998, specialist analytical company Xceleron has a global client base and primarily designs preclinical and clinical investigations around the unique analytical features of AMS to improve R&D efficiency.
Michael Butler, Chief Executive of Xceleron, said: 'Our customers have preferentially developed late-stage assets over the past five years and the lessons learned point towards a greater role for science and technology in early biopharmaceutics. I believe our alliance with Molecular Profiles is firmly at the centre of this current opportunity and market need.
'Looking at Molecular Profiles’ Roadmap to Clinical Trials platform, we believe there is an opportunity to add our complementary analytical technology to the process. This gives our clients the option to investigate the impact of solid state and formulations on human disposition at a very early stage.'